A separate randomized, double-blind, placebo-controlled Phase 2 trial in 2018 demonstrated that adjunctive oral verapamil, when combined with standard insulin therapy, enhanced endogenous β-cell function and reduced exogenous insulin requirements and hypoglycemic episodes in adults with recent-onset type 1 diabetes (T1D) [51]. Here, INS is linked to type 1 diabetes mellitus.